Vanguard Group
JUNO

Vanguard Group’s Juno Therapeutics, Inc. JUNO Stock Holding History

Vanguard Group’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,993,901
Closed -$320M – 4126
2017
Q4 		$320M Buy
6,993,901
+278,148
+4% +$13.9M 0.01% 984
2017
Q3 		$301M Buy
6,715,753
+430,077
+7% +$14.7M 0.01% 993
2017
Q2 		$188M Buy
6,285,676
+131,864
+2% +$3.25M 0.01% 1267
2017
Q1 		$137M Buy
6,153,812
+303,912
+5% +$6.52M 0.01% 1477
2016
Q4 		$110M Buy
5,849,900
+215,963
+4% +$5.28M 0.01% 1563
2016
Q3 		$169M Buy
5,633,937
+162,287
+3% +$5.05M 0.01% 1225
2016
Q2 		$210M Buy
5,471,650
+707,140
+15% +$29.4M 0.01% 1027
2016
Q1 		$181M Buy
4,764,510
+149,155
+3% +$5.2M 0.01% 1078
2015
Q4 		$203M Buy
4,615,355
+238,110
+5% +$11.8M 0.01% 996
2015
Q3 		$178M Buy
4,377,245
+2,979,416
+213% +$131M 0.01% 1065
2015
Q2 		$74.5M Buy
1,397,829
+44,697
+3% +$2.37M 0.01% 1722
2015
Q1 		$82.1M Buy
1,353,132
+1,283,132
+1,833% +$62.3M 0.01% 1637
2014
Q4 		$3.65M Buy
+70,000
New +$3.13M ﹤0.01% 3046

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Vanguard Group's JUNO Position: Q1 2018 in Review

Vanguard Group sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 6,993,901 shares — an estimated $320M sold.

Vanguard Group first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $320M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Vanguard Group reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Vanguard Group sold 6,993,901 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $320M.
  • Vanguard Group first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Vanguard Group's Juno Therapeutics, Inc. position peaked at $320M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Vanguard Group's 13F filing for Q1 2018, filed 15 May 2018.